本土创新药企全球化之路突围 投资人关注这些重点

Core Viewpoint - The article discusses the necessary steps for Chinese innovative pharmaceutical companies to evolve into multinational corporations (MNCs) in the global market, emphasizing the importance of research speed, differentiation advantages, and the overall quality of scientists [1][2]. Group 1: Market Performance and Trends - In the first half of 2025, China saw over 50 transactions related to innovative drugs, with upfront payments for license-out deals totaling $3.3 billion and total transaction amounts reaching $48.484 billion [2]. - The National Medical Products Administration reported that 43 innovative drugs were approved in the first half of 2025, marking a 59% year-on-year increase, nearing the total of 48 for the entire year of 2024 [2]. - China's innovative drug R&D pipeline accounts for approximately 25% of the global total, with around 3,000 clinical trials conducted annually, placing it among the world leaders [2]. Group 2: Key Factors for Success - The Chief Scientist of Shanghai Pharmaceuticals, Cai Xuejun, highlighted that in the AI era, research speed is crucial for the development of Chinese innovative drug companies, along with ensuring the authenticity of research data [2][3]. - Investment logic is clearer in areas such as immunity, metabolism, cardiovascular diseases, and Alzheimer's disease, with a focus on the potential for drug development and returns [3]. - Companies must enhance their unique core competencies and align their research with clinical needs while being willing to abandon less promising projects [3]. Group 3: Investment Considerations - Baiyang Pharmaceutical Group's VP of Research Management, Li Lihua, emphasized evaluating innovative drug projects based on their market segment, lifecycle, differentiation advantages, and R&D efficiency [4]. - Projects in emerging segments with no established products carry higher risks, while those in growth phases, like Alzheimer's disease, are more favorable for investment [4]. Group 4: Pathways to Becoming MNCs - Data indicates that by 2024, the number of innovative drugs under development in China will reach 3,575, positioning the country as a global leader [5]. - The CEO of Sullivan Jieli Trading Bao, Wan Yong, noted that Chinese companies can leverage their experiences in universal healthcare systems to expand into Southeast Asia and Africa, where population growth is expected [6]. - The concept of Real World Asset (RWA) tokenization is emerging as a new avenue for pharmaceutical companies to participate in capital markets, exemplified by Hanyu Pharmaceutical's recent project [6]. Group 5: Strategies for Global Expansion - To become true MNCs, pharmaceutical companies should adopt a product-driven approach to enter each country's market, establishing local teams and adapting to local regulations [7]. - Building a local sales network and ensuring drug registration and marketing are essential for success in foreign markets [7]. - The example of BeiGene, which has achieved drug sales in the U.S. and Europe, illustrates the lengthy process of global market entry, which can exceed five years [7].